Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
| Autor: | Handolias D; Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia., Hamilton AL, Salemi R, Tan A, Moodie K, Kerr L, Dobrovic A, McArthur GA |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | British journal of cancer [Br J Cancer] 2010 Apr 13; Vol. 102 (8), pp. 1219-23. Date of Electronic Publication: 2010 Apr 06. |
| DOI: | 10.1038/sj.bjc.6605635 |
| Abstrakt: | Background: Mutations in KIT are more frequent in specific melanoma subtypes, and response to KIT inhibition is likely to depend on the identified mutation. Methods: A total of 32 patients with metastatic acral or mucosal melanoma were screened for mutations in KIT exons 11, 13 and 17. Results: KIT mutations were found in 38% of mucosal and in 6% of acral melanomas. Three patients were treated with imatinib and one with sorafenib. All four patients responded to treatment, but three have since progressed within the brain. Conclusion: The observed clinical responses support further investigation of KIT inhibitors in metastatic melanoma, selected according to KIT mutation status. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|